EGS Beteiligungen AG exercises right to convert bond and increases its
shareholding in Siegfried to 6.2% registered shares

   Siegfried AG / Key word(s): Bond
   EGS Beteiligungen AG exercises right to convert bond and
   increases its shareholding in Siegfried to 6.2% registered shares
   14-Jun-2024 / 06:30 CET/CEST
   Release of an ad hoc announcement pursuant to Art. 53 LR
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   EGS Beteiligungen AG exercised its right to convert one of the
   convertible bonds issued in December 2020 with a coupon of 0.650%
   and a nominal value of CHF 40m into shares. EGS Beteiligungen
   will receive 51'899 shares of Siegfried Holding AG and as a
   result will increase its stake in Siegfried from 5.0% to about
   6.2% registered shares (about 7.2% including remaining purchase
   position). The shares will be delivered from Siegfried's treasury
   shares without issuance of new shares.

   As announced in December 2020, EGS Beteiligungen AG participated
   in the financing of Siegfried's acquisition of two pharmaceutical
   production sites in Spain through two hybrid convertible bonds
   issued by Siegfried. These bonds grant EGS Beteiligungen the
   right to convert the bonds into shares of Siegfried Holding AG
   when certain conditions are met.

   Siegfried's CEO ad interim Reto Suter: 'This conversion
   significantly increases the shareholding of EGS Beteiligungen AG
   and demonstrates its trust in Siegfried.'

Contact

   Financial Analysts:     Media:
   Dr. Reto Suter          Peter Stierli
   Chief Financial Officer Head Corporate Communications
   reto.suter@siegfried.ch peter.stierli@siegfried.ch
   Tel. +41 62 746 11 35   Tel. +41 62 746 15 51

Siegfried Holding AG

Untere Bruehlstrasse 4

CH-4800 Zofingen

   About Siegfried
   The Siegfried Group is a global life sciences company with sites
   in Switzerland, Germany, Spain, France, Malta, the USA and China.
   In 2023, the company achieved sales of CHF 1.272 billion and
   employed on 31.12.2023 more than 3'700 people at twelve sites on
   three continents. Siegfried Holding AG is publicly listed on SIX
   Swiss Exchange (SIX: SFZN).
   Siegfried is active in manufacturing pharmaceutical APIs (and
   their intermediates) as well as drug products (tablets, capsules,
   sterile vials, ampoules, cartridges and ointments) for the
   pharmaceutical industry and provides development services.
   Cautionary Statements Regarding Forward-Looking Statements
   This media release includes statements concerning the future.
   They are based on assumptions and expectations that may prove to
   be wrong. They should be considered with due caution as, by
   definition, they contain known and unknown risks, insecurities
   and other factors which could result in a difference in the
   actual results, financial situation, developments or the success
   of Siegfried Holding AG or Siegfried Group from the explicit or
   implicit assumptions made in these statements.

expect more

   Siegfried AG
   Untere Brühlstrasse 4
   4800 Zofingen, Switzerland
   +41 62 746 11 11
   info@siegfried.ch
   www.siegfried.ch

   Additional features:
   File:
   https://eqs-cockpit.com/c/fncls.ssp?u=8b367658100ce26d58511391b2334a9c
     ____________________________________________________________

   End of Inside Information
     ____________________________________________________________

   Language:    English
   Company:     Siegfried AG
                Untere Brühlstrasse 4
                4800 Zofingen
                Switzerland
   Phone:       +41 62 746 11 11
   E-mail:      info@siegfried.ch
   Internet:    https://www.siegfried.ch
   ISIN:        CH0014284498
   Listed:      SIX Swiss Exchange
   EQS News ID: 1924909

   End of Announcement EQS News Service
     ____________________________________________________________

1924909 14-Jun-2024 CET/CEST